Investor Relations

Stock Quote (NASDAQ: DNDN)
Price:
14.17
Change:
+ 0.23
Volume:
6,067,700
4:00 PM ET on Feb 3, 2012
Delayed at least 20 minutes.
Provided by eSignal.
Stock price graph
     

Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.

View all »   RSSRecent Releases

Feb 1, 2012
Dendreon to Host Conference Call on February 27 to Announce Fourth Quarter and Year-End Financial Results and Webcast Presentations at Upcoming Conferences

Feb 1, 2012
Dendreon Announces CEO and Chairman Succession Plan

Jan 31, 2012
Dendreon Announces Presentation of PROVENGE Data at the ASCO 2012 Genitourinary Cancers Symposium



View all »Webcasts

Feb 29, 2012 at 2:00 PM ET
Citi 2012 Global Healthcare Conference

Feb 27, 2012 at 4:30 PM ET
Q4 and Year End 2011 Earnings Conference Call



View all »Presentations

MEDCAC 11.17.10 Presentation PDF 397.5 KB
Updated Results of the IMPACT Trial of Sipuleucel-T for Metastatic, Castration-Resistant Prostate Cancer (CRPC) PDF 421.1 KB

Contact

Investor Relations
206-455-2220
ir@dendreon.com

Media
206-829-1622
media@dendreon.com